Akebia Therapeutics, Inc. (AKBA)
- Previous Close
1.3300 - Open
1.3200 - Bid 1.2900 x 500
- Ask 1.3400 x 100
- Day's Range
1.2950 - 1.3500 - 52 Week Range
0.7800 - 2.4800 - Volume
2,475,964 - Avg. Volume
4,836,728 - Market Cap (intraday)
280.558M - Beta (5Y Monthly) 0.84
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2800 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
www.akebia.comRecent News: AKBA
Performance Overview: AKBA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AKBA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AKBA
Valuation Measures
Market Cap
280.56M
Enterprise Value
285.75M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.29
Price/Book (mrq)
--
Enterprise Value/Revenue
1.47
Enterprise Value/EBITDA
-70.61
Financial Highlights
Profitability and Income Statement
Profit Margin
-26.68%
Return on Assets (ttm)
-9.31%
Return on Equity (ttm)
--
Revenue (ttm)
194.62M
Net Income Avi to Common (ttm)
-51.92M
Diluted EPS (ttm)
-0.2800
Balance Sheet and Cash Flow
Total Cash (mrq)
42.92M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
22.11M